Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• KRAS mutations are common drivers in non-small cell lung cancer (NSCLC) and colorectal cancer.
• KRAS G12C mutations, once difficult to target, are now addressed by approved therapies sotorasib and adagrasib.
• Existing KRAS G12C inhibitors have shown limited survival benefits and significant toxicities.

Purpose of the Study:

• To evaluate the preclinical potency and selectivity of divarasib compared to existing KRAS G12C inhibitors.
• To assess the clinical efficacy and safety profile of divarasib in a Phase I dose expansion cohort.
• To contextualize divarasib's findings within the evolving landscape of KRAS G12C-targeted therapies.

Main Methods:

• Preclinical comparative studies of divarasib, sotorasib, and adagrasib.
• Phase I dose expansion cohort study of divarasib in patients with KRAS G12C mutations.
• Analysis of objective response rate (ORR) and progression-free survival (PFS).

Main Results:

• Divarasib demonstrated 5-20x greater potency and up to 50x greater selectivity than sotorasib and adagrasib in preclinical models.
• In the Phase I cohort, divarasib achieved a 53.4% ORR and 13.1-month PFS.
• While toxicities were reported, the majority were low-grade and manageable with supportive care.

Conclusions:

• Divarasib exhibits superior preclinical potency and selectivity for KRAS G12C.
• Divarasib shows promising clinical efficacy and a manageable safety profile in early-stage trials.
• Divarasib represents a potential advancement in the treatment of KRAS G12C-mutated cancers.